← Mechanisms of action
CD5
SINGLE PROTEINHomo sapiens
Preferred name: T-cell surface glycoprotein CD5 ChEMBL ↗
Linked proteins
Drugs acting on this target (13)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| H65 | Adcc | experimental | mAb | CD5 |
| L17F12 | Adcc | experimental | mAb | CD5 |
| 90Y-t101 | Binding agent | experimental | mAb | CD5 |
| telimomab aritox | Binding agent | experimental | mAb | CD5 binding agent |
| zolimomab aritox | Binding agent | experimental | mAb | CD5 binding agent |
| c9/cd5car/il-15 nk cells | Immunity, passive | experimental | Cell therapy | CD5 immunity, passive |
| car.5/il15-transduced cb-nk cells | Immunity, passive | experimental | Cell therapy | CD5 immunity, passive |
| cd5 car-t cells | Immunity, passive | experimental | Cell therapy | CD5 immunity, passive |
| cd5.car/28zeta car t cells | Immunity, passive | experimental | Cell therapy | CD5 immunity, passive |
| ct125a cells | Immunity, passive | experimental | Cell therapy | immunity, passive - CD5 |
| senza5 cart5 | Immunity, passive | experimental | Cell therapy | CD5 immunity, passive |
| telimomab aritox | Inhibitor | experimental | mAb | CD5 inhibitor |
| zolimomab aritox | Inhibitor | experimental | mAb | CD5 inhibitor |